Swiss Life Asset Management Ltd Lowers Stock Position in United Therapeutics Corporation $UTHR

Swiss Life Asset Management Ltd lessened its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 48.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,599 shares of the biotechnology company’s stock after selling 7,031 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in United Therapeutics were worth $3,186,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AE Wealth Management LLC raised its holdings in United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its position in shares of United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares in the last quarter. Optimize Financial Inc purchased a new stake in shares of United Therapeutics in the third quarter valued at approximately $444,000. Simplify Asset Management Inc. acquired a new position in shares of United Therapeutics during the 3rd quarter worth approximately $8,351,000. Finally, Osaic Holdings Inc. lifted its position in shares of United Therapeutics by 271.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock valued at $14,027,000 after buying an additional 33,662 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research analyst reports. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, Wells Fargo & Company upped their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $548.09.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $524.28 on Monday. The stock’s fifty day moving average is $490.39 and its two-hundred day moving average is $468.92. The firm has a market capitalization of $22.98 billion, a P/E ratio of 18.79, a PEG ratio of 1.89 and a beta of 0.84. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $548.12.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.19 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $479.51, for a total transaction of $10,788,975.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.91, for a total transaction of $4,654,145.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $63,688.30. The trade was a 98.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 318,870 shares of company stock worth $156,760,844. 10.30% of the stock is owned by insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.